Zobrazeno 1 - 10
of 790
pro vyhledávání: '"selinexor"'
A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma
Autor:
Mohamed A. Gouda, Bettzy Stephen, Yanyan Tian, Anas Alshawa, Dilichukwu O. Chudy Onwugaje, Aya Albittar, Yali Yang, Abdulrazzak Zarifa, Bulent Yilmaz, Serdar Gurses, Ashabari Sprenger, Mohamed H. Derbala, Amanda Brink, Jeffrey Andrew How, Justin Moyers, Sarina A. Piha-Paul, David S. Hong, Funda Meric-Bernstam, Sapna P. Patel, Isabella Glitza Oliva
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Vol 7, Iss 4, Pp 247-254 (2024)
Introduction: Immune checkpoint inhibitors (ICIs) have substantially advanced the treatment of patients with malignant melanoma. However, improving therapeutic efficacy requires identifying drug combinations that elicit durable responses without indu
Externí odkaz:
https://doaj.org/article/01ddbd01535c420dae060977a04da2eb
Autor:
Nini Aung, Margaret Bowers, Gillian Brearton, Andrew Charlton, Joanne Craig, Jonathan Cullis, Ray Dang, David Donaldson, Mary Drake, Rachel Hall, Elizabeth Parkins, Jane Tighe, Ceri Bygrave, Oonagh Sheehy
Publikováno v:
eJHaem, Vol 5, Iss 5, Pp 987-991 (2024)
Abstract This report describes the characteristics and outcomes of 18 heavily pretreated patients with multiple myeloma (MM) who were subsequently treated with selinexor. This is a case series of 18 patients with MM who were treated with selinexor an
Externí odkaz:
https://doaj.org/article/456cfae128ad4e339dda45d427858acc
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
The treatment of elderly patients diagnosed with acute myeloid leukemia (AML) poses significant challenges. Currently, one promising strategy in therapeutic interventions for geriatric individuals revolves around the utilization of small molecule tar
Externí odkaz:
https://doaj.org/article/e950632b7ff24bc19420d680b7963834
Autor:
Yi Liu, Runyu Yang, Hui Feng, Yue Du, Bingyu Yang, Mengyao Zhang, Pengcheng He, Bohan Ma, Fan Niu
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract As the world's first oral nuclear export inhibitor, selinexor is increasingly being used in clinical applications for malignant tumors. However, there is no extensive exploration on selinexor's adverse events (ADEs), necessitating a real-wor
Externí odkaz:
https://doaj.org/article/5ee51b596237434790b50c193f8539d0
Publikováno v:
Clinical and Translational Discovery, Vol 4, Iss 4, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/9282ea0b14734a368ffb270b38ebfec9
Autor:
Lucio N. Gordan, David Ray, Stephen C. Ijioma, George Dranitsaris, Amanda Warner, Trevor Heritage, Matthew Fink, David Wenk, Paul Chadwick, Natasha Khrystolubova, Shachar Peles
Publikováno v:
Current Oncology, Vol 31, Iss 1, Pp 501-510 (2024)
Best practice (BP) in cancer care consists of a multifaceted approach comprising individualized treatment plans, evidence-based medicine, the optimal use of supportive care and patient education. We investigated the impact of a BP program in patients
Externí odkaz:
https://doaj.org/article/03fbdb730e0f4021a45793e1fd5c3ec3
Autor:
Mélody Caillot, Hadjer Miloudi, Antoine Taly, Nuria Profitós‐Pelejà, Juliana C. Santos, Marcelo L. Ribeiro, Elsa Maitre, Simon Saule, Gaël Roué, Fabrice Jardin, Brigitte Sola
Publikováno v:
Molecular Oncology, Vol 17, Iss 12, Pp 2546-2564 (2023)
Exportin 1 (XPO1) is the main nuclear export receptor that controls the subcellular trafficking and the functions of major regulatory proteins. XPO1 is overexpressed in various cancers and small inhibitors of nuclear export (SINEs) have been develope
Externí odkaz:
https://doaj.org/article/15e5148ed1e04b5480ee7573912d7a4b
Autor:
Darrell White, Gary J. Schiller, Sumit Madan, Suzanne Lentzsch, Evgeni Chubar, Noa Lavi, Dane R. Van Domelen, Ohad S. Bentur, Muhamed Baljevic
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
ObjectiveTo identify the optimal dose of selinexor in combination with pomalidomide and dexamethasone (SPd).MethodsAn analysis of efficacy and safety of 2 once-weekly selinexor regimens (60 mg and 40 mg) with pomalidomide and dexamethasone (SPd-60 an
Externí odkaz:
https://doaj.org/article/faf3645ed4d642638bc528022e510fa6
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Selinexor, a selective inhibitor of nuclear export (SINE), is gaining recognition beyond oncology for its potential in anti-inflammatory therapy. This review elucidates Selinexor’s dual action, highlighting its anti-tumor efficacy in various cancer
Externí odkaz:
https://doaj.org/article/7d4a9d1476024d599a5c6241002f94f4
Autor:
Xiaolu Long, Ning An, Chunhui Li, Hui Zhu, Haojie Li, Qiuxia Yu, Yimei Que, Menglei Xu, Zhe Li, Wei Chen, Shuai Wang, Di Wang, Chunrui Li
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
The outcome of AL amyloidosis remains poor, particularly in patients with advanced organ involvement which takes long time to recovery. We conducted an observational study of two patients with AL amyloidosis treated with SDd regimen. Both patients su
Externí odkaz:
https://doaj.org/article/a3e188e780cc45aa8108badce038c569